| 지원과제 |
PRCDM |
| 저자명 |
Park JY,Shon JH, Kim KA, Jung HJ, Shim JC, Yoon YR, Cha IJ, and Shin JG |
| 학회정보 |
Journal of Clinical Psychopharmacology, Volume 26, Number 2, April 2006 |
| 제 목 |
Combined Effects of Itraconazole and CYP2D6*10 Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Haloperidol in Healthy Subjects |
| LINK |
LINK |
| 게시일 |
2006-04-25 17:52:39 |
| 년도 |
2006-International |
| 내용 |
Abstract: This study was to evaluate the combined effects of the CYP3A4 inhibitor itraconazole and the CYP2D6*10 genotype on the pharmacokinetics and pharmacodynamics of haloperidol, a substrate of both CYP2D6 and CYP3A4, in healthy subjects. Nineteen healthy volunteers whose CYP2D6 genotypes were predetermined were enrolled (9 for CYP2D6*1/*1 and 10 for CYP2D6*10/*10). Four subjects (1 for CYP2D6*1/*1 and 3 for CYP2D6*10/*10) did not complete the study because of adverse events. The pharmacokinetics of haloperidol and its pharmacodynamic effects measured by QTc prolongation and neurologic side effects were evaluated after a single dose of 5 mg haloperidol following a pretreatment of placebo or itraconazole at 200 mg/d for 10 days in a randomized crossover manner. Itraconazole pretreatment increased the mean area under the time |
